This effect is associated with the release and activation of ILC2s in the lungs of mice [135]
As childhood obesity and youth-onset type 2 diabetes mellitus (T2DM) continue to rise worldwide, a new systematic review highlights glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as promising options that extend beyond lifestyle modification and metformin
(Details about these programs are not yet available.) These lifestyle support programs will be provided by participating manufacturers
Furthermore, it seems that the sample size, the dose and CLA isomer used, the duration of the intervention, the health status of the participants as well as the type of placebo are effective in response to treatment and are the cause of differences in the results of CLA supplementation studies
According to a study by Yang et al., GLP-1RAs improve glycemic control and insulin sensitivity in septic patients, thereby alleviating metabolic stress and reducing the risk of organ damage
Same molecule family, completely different regulatory universe